Zevra publishes four-year real-world U.S. early access data on MIPLYFFA in Niemann-Pick disease type C
Reuters2026/08/03 11:30- Zevra Therapeutics published four-year real-world data from its U.S. early access program for MIPLYFFA (arimoclomol) in Niemann-Pick disease type C.
- Results were presented as a peer-reviewed journal publication, not a future conference readout.
- Findings indicated patients’ overall disease status stayed broadly stable over time in routine clinical practice, including in adults.
- Safety observations aligned with the therapy’s established profile, supporting continued use alongside miglustat in eligible patients.
- The report reinforces the product’s commercial positioning following its U.S. clearance in 2024, with an EU filing under review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Energy Chief Says Fuel Export Ban Wouldn't Lower Prices
Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk
Costco Wholesale Nearly Doubles Kirkland Motor Oil Price, Caps Purchases at Two Weekly
Liquidity Unconcerned? The Federal Reserve Hits 'Pause' Again, Ceasing Reserve Management Bond Purchases Until Mid-October
The Federal Reserve announced on Monday that it will not conduct short-term Treasury bond purchases for reserve management purposes in the next phase for the second consecutive month, indicating that policymakers are satisfied with the level of bank reserves in the financial system.
Crypto prices
More
